Serum Myostatin Mediates Muscle-Kidney Axis and is an Independent Risk Factor for Diabetic Kidney Disease: A Cross-Sectional Study and Mediation Analysis

Abstract Aims The relationship of serum myostatin, implicated in sarcopenia and diabetic kidney disease (DKD), with DKD is not understood. This study explores the independent association between myostatin levels and DKD, its relationship with renal injury severity in type 2 diabetes mellitus (T2DM) patients, and its role as a muscle-kidney axis biomarker. Materials and methods In total, 216 T2DM patients were enrolled. Hierarchical multivariable logistic and linear regression analyses were conducted for independent associations of serum myostatin with DKD and renal injury markers. Causal mediation analysis with bootstrap resampling was performed for mediating effects of myostatin on the bidirectional relationship between renal impairment and skeletal muscle dysfunction. ROC curve analysis was used for the discriminative performance of serum myostatin in identifying DKD. Results Myostatin levels were higher in DKD patients compared to DKD (3.47 vs. 1.66 ng/mL, p < 0.001). Log-transformed serum myostatin levels were associated with DKD prevalence (OR = 1.93, 95% CI: 1.29–2.95, p = 0.002) and urinary albumin-to-creatinine ratio (UACR) (β = 0.308, p = 0.007). Indirect effects of myostatin in the renal injury-to-muscle dysfunction and the reciprocal muscle dysfunction-to-renal injury pathways were identified. Incorporating serum myostatin into traditional risk prediction models improved diagnostic discrimination for DKD, increasing the AUC from 0.665 to 0.803 ( p < 0.001). Conclusion Higher serum myostatin levels are associated with increased DKD risk and severe renal injury in T2DM patients. Myostatin may be a molecular component of the muscle-kidney axis and a biomarker for early DKD risk stratification, disease monitoring, and targeted intervention. Trial registration: Chinese Clinical Trial Registry (ChiCTR2500106905, 2025-07-31)

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11549314/v1
Primary Topic
Chronic Kidney Disease and Diabetes
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Serum Myostatin Mediates Muscle-Kidney Axis and is an Independent Risk Factor for Diabetic Kidney Disease: A Cross-Sectional Study and Mediation Analysis

Anni Luo, Chenyu Han, Yarong Wang, Yaxuan Zhang et al.
Research Square
Chronic Kidney Disease and Diabetes
preprint

Serum Myostatin Mediates Muscle-Kidney Axis and is an Independent Risk Factor for Diabetic Kidney Disease: A Cross-Sectional Study and Mediation Analysis

Anni Luo, Chenyu Han, Yarong Wang, Yaxuan Zhang, Haotian Gu, Min Zhang, Siyuan Shen, Haiying Jin
preprint en

Abstract

Abstract Aims The relationship of serum myostatin, implicated in sarcopenia and diabetic kidney disease (DKD), with DKD is not understood. This study explores the independent association between myostatin levels and DKD, its relationship with renal injury severity in type 2 diabetes mellitus (T2DM) patients, and its role as a muscle-kidney axis biomarker. Materials and methods In total, 216 T2DM patients were enrolled. Hierarchical multivariable logistic and linear regression analyses were conducted for independent associations of serum myostatin with DKD and renal injury markers. Causal mediation analysis with bootstrap resampling was performed for mediating effects of myostatin on the bidirectional relationship between renal impairment and skeletal muscle dysfunction. ROC curve analysis was used for the discriminative performance of serum myostatin in identifying DKD. Results Myostatin levels were higher in DKD patients compared to DKD (3.47 vs. 1.66 ng/mL, p < 0.001). Log-transformed serum myostatin levels were associated with DKD prevalence (OR = 1.93, 95% CI: 1.29–2.95, p = 0.002) and urinary albumin-to-creatinine ratio (UACR) (β = 0.308, p = 0.007). Indirect effects of myostatin in the renal injury-to-muscle dysfunction and the reciprocal muscle dysfunction-to-renal injury pathways were identified. Incorporating serum myostatin into traditional risk prediction models improved diagnostic discrimination for DKD, increasing the AUC from 0.665 to 0.803 ( p < 0.001). Conclusion Higher serum myostatin levels are associated with increased DKD risk and severe renal injury in T2DM patients. Myostatin may be a molecular component of the muscle-kidney axis and a biomarker for early DKD risk stratification, disease monitoring, and targeted intervention. Trial registration: Chinese Clinical Trial Registry (ChiCTR2500106905, 2025-07-31)

Research Square
Fudan University (CN), Zhongshan Hospital (CN)
Good health and well-being
Chronic Kidney Disease and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon